[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dermatitis-atopic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dermatitis-atopic":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,41,79,101,134,157,184,206,226,254,275,296,326,350],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100534614","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-subcutaneous-amlitelimab-on-background-topical-corticosteroids-therapy-in-participants-aged-12-years-and-older-with-moderate-to-severe-ad-who-have-had-an-inadequate-response-to-prior-biologic-therapy-or-an-oral-jak-inhibitor-100534614",false,"NCT06241118","A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor","A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment","AQUA","Inclusion Criteria:\n\n* Participants must be 12 years of age (when signing informed consent form)\n* Diagnosis of AD for at least 1 year (defined by the American Academy of Dermatology Consensus Criteria)\n* Documented history prior to screening visit of inadequate response to a biologic AD medication or an oral JAKi therapy.\n* v-IGA-AD of 3 or 4 at baseline visit\n* EASI score of 16 or higher at baseline\n* AD involvement of 10% or more of BSA at baseline\n* Weekly average of daily PP-NRS of ≥ 4 at baseline visit.\n* Able and willing to comply with requested study visits and procedures\n* Body weight ≥25 kg\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Skin co-morbidity that would adversely affect the ability to undertake AD assessments\n* Known history of or suspected significant current immunosuppression\n* Any malignancies or history of malignancies prior to baseline (with the exception of non-melanoma skin cancer excised and cured \\>5 years prior to baseline)\n* History of solid organ or stem cell transplant\n* Any active or chronic infection including helminthic infection requiring systemic treatment within 4 weeks prior to baseline\n* Positive for human immunodeficiency virus (HIV), Hepatitis B or hepatitis C at screening visit\n* Having active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB\n* Having received any of the specified therapy within the specified timeframe(s) prior to the baseline visit\n* In the Investigator's opinion, any clinically significant laboratory results or protocol specified laboratory abnormalities at screening\n* History of hypersensitivity or allergy to any of the excipients or investigational medicinal product (IMP)\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial","ALL","12 Years",{"count":20,"type":21},636,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy.\n\nThe purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy.\n\nStudy details include:\n\nAt the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD).\n\nThe study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 \\[RIVER-AD\\]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up.\n\nThe study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 \\[RIVER-AD\\]) including a 2 to 4-week screening and a 36-week randomized double-blind period.\n\nThe total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 \\[RIVER-AD\\] study).",[27],"Dermatitis Atopic","RECRUITING","2026-07-01",{"date":31,"type":32},"2026-07-02","ACTUAL",{"date":34,"type":32},"2024-02-29",{"date":36,"type":21},"2028-09-29",{"name":38,"class":39},"Sanofi","INDUSTRY",150,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":62,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100181078","phase-2-effects-of-treatments-on-atopic-dermatitis-100181078","NCT01631617","Effects of Treatments on Atopic Dermatitis","Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic Dermatitis","* INCLUSION CRITERIA:\n\nCohorts 1 \\[NO FURTHER ACCRUAL\\], 2 \\[INACTIVE\\], 4 \\[NO FURTHER ACCRUAL\\] and 5 \\[INACTIVE\\]: Healthy Volunteers\n\n* Males and females aged 18-50 years at time of initial protocol sampling\n* Subjects must participate fully and be willing to comply with the procedures of the protocol\n* Subjects must be co-enrolled in NIH protocol 08-HG-0059\n* Ability of subject to understand and provide written informed consent\n* Access to bathing facilities (Cohort 2 \\[INACTIVE\\])\n* Ability to swallow capsules or tablets\n\nCohort 3 \\[INACTIVE\\]: Atopic Dermatitis Patients\n\n* Subjects must be aged 2-50 years\n* Subjects must be co-enrolled in NIH protocol 08-HG-0059\n* Subjects must have a diagnosis of atopic dermatitis on the basis of the criteria defined by UK Working Party s Diagnostic Criteria for Atopic Dermatitis\n* Subjects must have a primary care provider\n* Subjects must have an Objective SCORAD (SCORing Atopic Dermatitis) of greater than or equal to 15 indicating AD severity of moderate to severe\n* Prior to initiation of randomized treatment, subjects must have signs of bacterial skin infections (skin weeping, crusting, and\u002For pustules)\n* Access to bathing facilities\n* All subjects and\u002For their Legally Authorized Representative (LAR) must have the ability and agree to participate fully and comply with\n\nthe procedures of the protocol and provide informed consent. Pediatric patients will be included in age appropriate discussions and\n\nage appropriate assent will be obtained in accordance with NIH guidelines.\n\n-Ability of subject to understand and provide written informed consent\n\nCohort 6: Healthy Volunteers\n\n* Subjects previously enrolled in Cohorts 1 \\[NO FURTHER ACCRUAL\\] and 4 \\[INACTIVE\\] who completed on-protocol antibiotic regimen\n* Subjects must participate fully and be willing to comply with the procedures of the protocol\n* Ability of subject to understand and provide written informed consent\n\nEXCLUSION CRITERIA:\n\nCohorts 1 \\[NO FURTHER ACCRUAL\\] and 2 \\[INACTIVE\\]: Healthy Volunteers\n\n* Does not meet inclusion criteria\n* Any female with symptoms and\u002For serum hormone levels consistent with perimenopause or menopause\n* Use of systemic antibiotics in 12 months preceding baseline sampling\n* Use of swimming pools, hot tubs, or whirlpools in 7 days preceding baseline sampling\n* Use of topical or oral complementary\u002Falternative medicine (CAM) agents within 4 weeks of initiation of treatment\n* Known allergic reaction to sulfa, beta-lactam, or tetracycline class drugs; or lidocaine or epinephrine\n* Family history of toxic epidermal necrolysis\n* Known allergy or sensitivity to sodium hypochlorite (NaOCl)\n* History of AD or asthma\n* Inability to comply with the requirements of the protocol\n* Pregnant or lactating\n* Subjects with a primary or acquired immunodeficiency, including HIV seropositiviy\n* Any chronic past or present medical illness, including chronic skin diseases like psoriasis\n* Subjects receiving or planning to receive an IND agent, ultraviolet light therapy, monoclonal antibodies, or systemic immunosuppressants\n* Subjects who provide direct healthcare or reside in healthcare facilities or in non-hospital settings such as, assisted living facilities, homeless shelters, jails and prisons as well as subjects with frequent exposure to laboratory animals\n\nCohort 3 \\[INACTIVE\\]: Atopic Dermatitis Patients\n\n* Does not meet inclusion criteria\n* Any female with symptoms and\u002For serum hormone levels consistent with perimenopause or menopause\n* Known allergic reaction to beta-lactam class drugs, lidocaine, or epinephrine\n* Family history of toxic epidermal necrolysis\n* Known allergic reaction to sodium hypochlorite (NaOCl)\n* Use of systemic antibiotics within 8 weeks, or topical antibiotics on intended sampling sites within 3 weeks, prior to baseline sampling\n* Use of topical corticosteroids on all intended sampling sites within 7 days, prior to baseline sampling\n* Use of topical or oral CAM agents within 4 weeks of initiation of treatment\n* Subjects with known primary or acquired immunodeficiency\n* Subjects with unstable or uncontrolled medical conditions that could require hospitalization during the initial month of the study or who have been hospitalized for treatment of these conditions in the one month prior to baseline sampling\n* Subjects receiving or planning to receive an IND agent, ultraviolet light therapy, monoclonal antibodies, or systemic immunosuppressants within 7 days or 5 half-lives (whichever is the longer time period) of initiating treatment on this protocol\n* Subjects who are currently receiving or have received chemotherapy or radiation for treatment of malignancies within the previous 6 months\n* Pregnancy or lactating\n\nCohorts 4 \\[NO FURTHER ACCRUAL\\] and 5 \\[INACTIVE\\]: Healthy Volunteers\n\n* Does not meet inclusion criteria\n* Any female with symptoms and\u002For serum hormone levels consistent with perimenopause or menopause\n* Use of systemic antibiotics in 12 months preceding baseline sampling\n* Use of swimming pools, hot tubs, or whirlpools in 7 days preceding baseline sampling\n* Use of topical or oral complementary\u002Falternative medicine (CAM) agents within 4 weeks of initiation of treatment\n* (Cohort 4 \\[NO FURTHER ACCRUAL\\]) Known allergic reaction to sulfa class drugs; or lidocaine or epinephrine\n* (Cohort 5 \\[INACTIVE\\]) Known allergic reaction to tetracycline class drugs; or lidocaine or epinephrine\n* Family history of toxic epidermal necrolysis\n* History of AD or asthma\n* Inability to comply with the requirements of the protocol\n* Pregnant or lactating\n* Subjects with a primary or acquired immunodeficiency, including HIV seropositivity\n* Any chronic past or present medical illness, including chronic skin diseases like psoriasis\n* Subjects receiving or planning to receive an IND agent, ultraviolet light therapy, monoclonal antibodies, or systemic immunosuppressants\n* Subjects who provide direct healthcare or reside in healthcare facilities or in non-hospital settings such as assisted living facilities, homeless shelters, jails and prisons as well as subjects with frequent exposure to laboratory animals\n\nCohort 6: Healthy Volunteers\n\n* Does not meet inclusion criteria\n* Use of swimming pools, hot tubs, or whirlpools in 7 days preceding sampling\n* Use of topical or oral CAM agents within 1 week or 4 weeks, respectively, prior to sampling\n* Pregnant or lactating females in all cohorts are excluded from participating due to the potential effects of the above listed antimicrobials on the developing human fetus or nursing infant; listed in Sections 11.1 through 11.5. Females of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Lactating mothers will discontinue breastfeeding prior to study enrollment.\n* Smokers and subjects who use smokeless tobacco products are excluded in all cohorts due to tobacco s unknown impact on human oral mucosa and microflora.",true,"2 Years","50 Years",{"count":52,"type":21},130,[54],"PHASE2","Background:\n\n\\- Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S. aureus bacteria. Researchers want to study how eczema treatments affect the number and the type of bacteria on the skin.\n\nObjectives:\n\n\\- To study the effect of eczema treatments on skin bacteria.\n\nEligibility:\n\n* Individuals between 2 and 25 years of age who have moderate to severe atopic dermatitis.\n* Healthy volunteers between 18 and 40 years of age with no history of eczema.\n\nDesign:\n\n* Participants will be screened with a physical exam and medical history. Research samples will be collected. Skin biopsies may also be performed.\n* All participants will be assigned to one of several study groups.\n* Healthy volunteers must not have taken antibiotics in the year before the start of the study.\n* All participants will have regular study visits during their 1-year participation. More research samples will be collected at these visits.\n* Healthy volunteers may be asked to come in for a one-time follow up after the 1 year mark.",[57,58,59,60,61],"Eczema","Dermatitis","Skin Diseases, Genetic","Dermatitis, Atopic","Skin Diseases",[63,64,65,66,67],"Investigator-Blinded","Skin Biopsy","Randomized","Antibiotics","Topical","2026-06-27",{"date":70,"type":32},"2026-06-30",{"date":72,"type":32},"2012-09-18",{"date":74,"type":21},"2027-01-01",{"name":76,"class":77},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","NIH",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100530882","a-study-to-observe-how-adolescent-patients-with-severe-atopic-dermatitis-despite-less-extensive-skin-lesions-eczema-area-and-severity-index-score--16-respond-to-dupilumab-treatment-100530882","NCT06192563","A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score \u003C 16) Respond to Dupilumab Treatment","A Prospective Observational Study of Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score \u003C 16) Receiving Dupilumab","AD-BEASCUITS","Inclusion Criteria:\n\n* Male or female, aged between 12 and 17 years at the baseline visit\n* Patients with AD who have been prescribed dupilumab according to Agenzia Italiana del Farmaco (AIFA) reimbursement criteria and fulfilling the following criteria:\n\nPatients with EASI\\\u003C16 and\n\n1. Children's Dermatology Life Quality Index (CDLQI) ≥ 10 or\n2. Peak Pruritus Numerical Rating Scale (PP-NRS) ≥ 7 or\n3. localization in visible or sensitive areas (head\u002Fneck\u002Fhands or genitals)\n\n   * Patients able to understand and complete study-related questionnaires\n   * Provided signed informed consent or parental\u002Flegally acceptable representative consent and patient assent where applicable\n\nExclusion Criteria:\n\n* Prior use of dupilumab within 6 months prior the study entry\n* Patients currently participating in any interventional clinical trial which modifies patient care\n* Any condition that, in the opinion of the Investigator, may interfere with patient's ability to participate in the study (e.g., substance abuse)\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.","17 Years",{"count":40,"type":21},"OBSERVATIONAL","In adolescents treated with dupilumab, clinical trials showed significant improvement of atopic dermatitis (AD) signs and symptoms, with a good safety profile. In these clinical trials, only patients with Eczema Area and Severity Index (EASI) score greater than or equal to (≥) 16 were enrolled, and effectiveness on sensitive\u002Fvisible areas was not specifically evaluated. Further data about the effectiveness of dupilumab in adolescent participants with moderate to mild EASI score and severe itching and\u002For localized AD are therefore necessary to better understand the potential clinical benefits of dupilumab in these populations.\n\nThis is an Italian multicenter, 52-week observational (non-interventional) study which will collect data on the characteristics of adolescent (aged 12 to 17 years) participants who suffer from severe AD with EASI score less than (\\\u003C) 16, eligible for systemic dupilumab treatment according to Italian reimbursement criteria. It will study the real-world effectiveness and safety of dupilumab in this population, the effect of dupilumab on itching (pruritus), sleep, quality of life and related outcomes, localized AD in sensitive\u002Fvisible areas, and on coexisting atopic conditions in adolescent participants who receive dupilumab for AD. It will also document dupilumab treatment satisfaction and dupilumab discontinuation in the study participants.",[27],"2026-06-24",{"date":94,"type":32},"2026-06-29",{"date":96,"type":32},"2023-11-30",{"date":98,"type":21},"2028-03-31",{"name":38,"class":39},9,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":48,"sex":17,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":78},"100642243","phase-1-a-first-in-human-study-to-investigate-single-doses-of-dcy636-in-healthy-volunteers-and-multiple-doses-in-participants-with-moderate-to-severe-atopic-dermatitis-100642243","NCT07604324","A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis","A Two-part, Randomized, Participant- and Investigator-blinded, Placebo Controlled First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of DCY636 in a Single Ascending Dose Part in Healthy Participants and in a Multiple Dose Part in Participants With Moderate to Severe Atopic Dermatitis","Key Inclusion Criteria:\n\nHealthy Participants (Part 1)\n\n• Healthy male and non-childbearing potential female participants 18 to 55 years of age inclusive.\n\nParticipants with moderate to severe atopic dermatitis (Part 2)\n\n* Males and non-pregnant females age 18 years or older\n* Diagnosis of atopic dermatitis for at least 1 year not adequately controlled by topicals\n* Moderate to severe atopic dermatitis as defined by all of the following:\n\n  * EASI score ≥12 at screening visit and ≥16 at baseline (BL) visit\n  * IGA score ≥3 at screening visit and baseline visit\n  * Total Body surface area (BSA) affected by AD ≥ 10 % at screening visit and baseline visit\n  * Peak Pruritus NRS score ≥4 at baseline visit, based on weekly average of daily assessment in the week prior to baseline visit\n\nKey Exclusion Criteria:\n\nAll Participants (Part 1, Part 2)\n\n* Use of other investigational drugs within the last 30 days or 5 half-lives of the other drugs prior to initial dosing, whichever is longer.\n* Meet any of the prohibited medication use criteria at baseline visit.\n* A positive syphilis test result during screening period.\n* Evidence of active or latent TB infection, as determined by T-Spot test during screening period.\n* History of immunodeficiency diseases, or a positive human immunodeficiency virus (HIV) test result.\n* Recent (within last half year) or ongoing helminth infection.\n* History of hepatitis B or hepatitis C or serologic evidence for viral hepatitis. A positive Hepatitis B virus surface antigen (HBsAg), Hepatitis B virus core antibody (HBcAb) and\u002For Hepatitis B surface antibody (HBsAb) test during screening period excludes a participant. A positive test for HBsAb can be included if the test for HBsAg and HBcAb are negative and the history of hepatitis B vaccination is known. Participants with a positive Hepatitis C virus (HCV) antibody test should be excluded.\n\nHealthy Participants (Part 1)\n\n* Women of childbearing potential\n* Smokers Participants with moderate to severe atopic dermatitis (Part 2)\n* Regular use (more than 2 visits per week) of a tanning booth\u002Fparlor or extended sun exposure (per investigator judgement) within 4 weeks prior to baseline visit\n* Have any chronic, uncontrolled medical condition, which would put the participant at increased risk during study participation, such as uncontrolled: diabetes, hypertension, morbid obesity, thyroid, adrenal, cardiovascular, pulmonary, hepatic, renal, neurologic or psychiatric disease, or other disease of concern, as per investigator judgment\n* Women of childbearing potential (WOCBP) are excluded unless they are using highly effective methods of contraception (failure rate \\\u003C 1% per year) while taking study treatment and for 202 days (= 5 times the terminal half-life) of study treatment after stopping study treatment.\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","18 Years","100 Years",{"count":111,"type":21},63,[113],"PHASE1","The purpose of this first-in-human (FIH) study is to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity (IG) and pharmacodynamics (PD) of DCY636. The results are intended to support the further clinical development of DCY636 in future studies.",[60],[117,118,119,120,121,122,123,124],"Phase 1","FIH","safety and tolerability","healthy volunteers","PK","atopic dermatitis","AD","eczema","2026-06-15",{"date":127,"type":32},"2026-06-16",{"date":129,"type":32},"2026-06-02",{"date":131,"type":21},"2028-01-28",{"name":133,"class":39},"Novartis Pharmaceuticals",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100610690","phase-2-a-study-of-jnj-95597528-in-participants-with-moderate-to-severe-atopic-dermatitis-100610690","NCT07230860","A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis","A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants With Moderate to Severe Atopic Dermatitis","READY-AD","Inclusion criteria:\n\n* Be otherwise healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening\n* Meets all the following disease activity criteria: a. Chronic atopic dermatitis (AD), according to American Academy of Dermatology Consensus Criteria with onset of symptoms at least 1 year prior to screening visit; b. Eczema area and severity index (EASI) score greater than or equal to (\\>=) 16 at the screening and Week 0; c. validated investigator global assessment for atopic dermatitis (vIGA-AD) score \\>= 3 at screening and Week 0; d. \\>= 10% body surface area (BSA) of AD involvement at screening and Week 0; e. Documented history (within 6 months before screening) of either inadequate response or inadvisability to medicated topical treatments for AD or inadequate response to systemic therapies (within 12 months before screening)\n* Must sign an informed consent form (ICF) indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study\n* If willing to participate in the substudy, must sign a separate ICF for the corresponding substudy (or substudies)\n* Willing and able to comply with scheduled visits, treatment plan, laboratory tests, lifestyle restrictions, and other study procedures\n\nExclusion criteria:\n\n* History of substance abuse or alcohol abuse within 1 year before screening\n* In the investigator's opinion, any clinically significant results from the 12-lead ECG, chemistry, hematology, or urinalysis laboratory tests obtained at the screening visit that would affect interpretation of study data or the participant's safety in the study\n* Known or suspected immunodeficiency, including history of invasive opportunistic infections\n* Previously received JNJ-95597528\n* Has known hypersensitivity or intolerance to JNJ-95597528 or its excipients or to any biologic medication or known allergies, or clinically significant reactions to murine, chimeric, monoclonal antibodies (mAbs), or antibody fragments",{"count":143,"type":21},180,[54],"The purpose of this study is to assess how well JNJ-95597528 works compared to placebo in participants with moderate to severe atopic dermatitis (AD).",[60],"2026-06-04",{"date":149,"type":32},"2026-06-05",{"date":151,"type":32},"2026-01-20",{"date":153,"type":21},"2028-02-10",{"name":155,"class":39},"Janssen Research & Development, LLC",62,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":183},"100637567","phase-2-a-phase-2b-study-of-the-effects-of-camoteskimab-in-adults-with-moderate-to-severe-atopic-dermatitis-100637567","NCT07599813","A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis","A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis","Inclusion Criteria:\n\n1. Age 18-65 inclusive, at the time of signing the informed consent.\n2. Chronic AD for at least 1 year based on clinically confirmed diagnosis of active AD, according to Hanfin and Rajka criteria.\n3. Participants with moderate-to-severe AD defined by:\n\n   1. Investigator global assessment (IGA) score of ≥ 3 (on a scale of 0 to 4, in which three is moderate and four is severe) at Screening and Baseline.\n   2. AD involvement of ≥ 10% body surface area (BSA) at Screening and Baseline.\n   3. EASI score of ≥ 16 at Screening and at Baseline.\n   4. Peak pruritus numerical rating scale (PP-NRS) ≥ 4 at Baseline. Note: The PP-NRS will be calculated from the 7 consecutive days immediately preceding Baseline. A minimum of 4 daily scores out of the 7 days is needed.\n4. Participants who are candidates for systemic therapy, defined as history of inadequate response to topical AD treatments applied for at least 28 days, or for the maximum duration recommended by the product prescribing information, or for treatment with topical AD treatments is medically inadvisable due to important side effects or safety risks.\n5. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n6. Participant provides signed informed consent\n\nExclusion Criteria:\n\n1. History or other evidence of severe illness or any other conditions such as psychiatric illness, severe depression or previous history of suicidal attempt in past 10 years that would render the participant, in the opinion of the Investigator, unsuitable for the study.\n2. Active, chronic or acute infection requiring systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the Baseline.\n3. Participant has a current diagnosis of other active skin disease (e.g., psoriasis or lupus erythematosus) or skin infection (bacterial, fungal, or viral) that may affect the evaluation of AD or would interfere with the study assessments based on the Investigator's judgement.\n4. Participant has history of significant flares of AD within 4 weeks prior to screening, in the opinion of the investigator.\n5. Participant has a severe comorbidity that may require systemic steroids therapy or other interventions or requires active frequent monitoring (e.g., unstable chronic asthma) based on investigator judgement.\n6. Any clinically significant abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically significant abnormalities in the 12-lead ECG as considered by the Investigator that may interfere with the interpretation of QTc interval changes.\n7. Participant has severe and uncontrolled seasonal or allergic rhinitis, severe and uncontrolled asthma or any other severe and uncontrolled atopic disease as judged by the Investigator.\n8. Treatment of AD with medicated moisturizers available only by prescription within 2 weeks prior to the Baseline visit.\n9. Active human immunodeficiency virus (HIV): confirmed positive anti-HIV antibody (HIV Ab) test.\n10. Active hepatitis B virus (HBV): hepatitis B surface antigen (HBs Ag) positive (+) or hepatitis B core antibody (HBc Ab) positive (+) confirmed by HBV PCR positive (+).\n11. Active hepatitis C virus (HCV): If hepatitis C antibody positive (+), confirmed by HCV RNA test. Note: a participant with documented proof of cure from HCV may be enrolled.\n12. Evidence of active or latent tuberculosis.\n13. Receipt of live or attenuated live vaccine within 6 weeks prior to screening.\n14. Participant had a major surgery within 8 weeks prior to Baseline or has a major surgery planned during the study.\n15. Participant is known to have immune deficiency or is immunocompromised\n16. Diagnosed with a malignancy within 5 years of enrollment (suspected malignancy should be ruled out by blood or tissue biopsy, as applicable) with the exception of:\n\n    * Completely resected basal cell or squamous cell carcinoma of the skin.\n    * Carcinoma in situ of the cervix.\n17. Has had previous exposure to anti-IL-18 therapy.\n18. Known allergy\u002Fsensitivity to any component of IMP.\n19. History of use of any of these medications as follows:\n\n    1. Dupilumab, tralokinumab, lebrikizumab, nemolizumab within 8 weeks prior to Baseline.\n    2. Systemic JAKi within 4 weeks prior to Baseline.\n    3. Any topical medicated treatment that could affect AD within 2 weeks prior to Baseline, including, but not limited to, topical corticosteroids, topical phosphodiesterase (PDE4) inhibitors, topical calcineurin inhibitors, topical JAKi, tars, antimicrobials, medical devices, and bleach baths.\n    4. Systemic therapies (other than biologics) that could affect AD not noted above, within 4 weeks prior to Baseline, including but not limited to, retinoids, calcineurin inhibitors, methotrexate, hydroxycarbamide (hydroxyurea), azathioprine, oral\u002Finjectable corticosteroids. Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed.\n    5. Treatment with any investigational biologic agent or biologic agent approved after publication of this protocol, within 12 weeks (or 5 half-lives, whichever is greater) of screening.\n    6. Treatment with any investigational nonbiologic agent, or any investigational device or procedure, within 4 weeks (or 5 half-lives, whichever is greater) of screening.\n    7. UV-B phototherapy (including tanning beds) or excimer laser use within 4 weeks prior to Baseline or during the study.\n    8. PUVA treatment within 4 weeks prior to Baseline\n    9. Sedating antihistamines, including but not limited to doxepin, hydroxyzine or diphenhydramine within 1 week prior to Baseline\n    10. Topical products containing urea within 1 week prior to Baseline\n    11. Systemic antibiotics within 2 weeks or topical antibiotics within 1 week prior to Baseline\n    12. Intravenous immunoglobulin (IVIg) therapy within 12 weeks prior to Baseline.\n20. Female participant who is pregnant or breastfeeding or trying to conceive.\n21. Participant considered unlikely to adhere to treatment and\u002For follow the protocol in the opinion of the Investigator.","65 Years",{"count":166,"type":21},280,[54],"This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.",[170,171,58,60,172,57,173,174],"Atopic Dermatitis","Atopic","Dermatologic Disease","Eczema Atopic Dermatitis","Eczema, Atopic","2026-05-29",{"date":129,"type":32},{"date":178,"type":32},"2026-05-28",{"date":180,"type":21},"2028-04-30",{"name":182,"class":39},"Apollo Therapeutics Ltd",85,{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":78},"100585195","real-world-efficiency-of-abrocitinib-treatment-at-patients-with-moderate-to-severe-atopic-dermatitis-who-had-inadequate-response-to-previous-biologic-therapies-100585195","NCT06899204","Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.","A Prospective, Multi-center Observational Study Characterizing Clinical Outcomes of Patients Receiving Abrocitinib for Moderate-to-severe Atopic Dermatitis Who Had an Inadequate Response (or Intolerance) to ≤2 Previous Biologic Therapies Approved for Moderate-to-severe Atopic Dermatitis","This NI study will enroll 150 patients from approximately 15 sites across the US. The study population eligible for enrollment includes adult and adolescent patients aged ≥12 years diagnosed with moderate to severe AD who receive at least one dose of abrocitinib and satisfy the inclusion and exclusion criteria. Patients who had inadequate response or intolerance to previous ≤2 biologic therapies will be included in this study as there is a lack of effectiveness data for abrocitinib in these patients. As this will be an observational study, there will be no sampling and all patients that meet the inclusion and exclusion criteria will be recruited consequently. The study will be open for enrollment for approximately 12 months after the first patient has been enrolled. Regarding the inclusion and exclusion criteria, in the real-world setting recruitment may be slower than expected, thus depending on the observed enrollment rate, the enrollment period and number of sites may be reassessed and revised during the study.\n\n9.2.1. Inclusion Criteria\n\nPatients must meet all of the following inclusion criteria to be eligible for inclusion in the study:\n\n1. Participants who have chronic AD that has been present for ≥1 year before screening.\n2. Male and female patients aged \\>12 years at baseline.\n3. Patients with diagnosis of moderate-to-severe atopic dermatitis confirmed by a certified dermatologist, who are prescribed abrocitinib for use in accordance with the product label (USPI) and independently of the decision to enroll the patient in this study\n4. Patients who have inadequate responses or are intolerant to ≤2 previous biologic therapy approved for M2S AD. (Patients shall have had an inadequate response and\u002For intolerance to at least one, but no more than 2 biologic therapies approved for moderate-to-severe AD)\n5. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Following receipt of oral and written information about the study, the adolescent (depending on local institutional review board\u002Findependent ethics committee requirements) must provide assent, and one or both (according to local regulations) parents or guardians of the child must provide signed informed consent before any study-related activity is carried out.\n6. Patients, who in the opinion of the investigator, are willing and able to comply with regular clinic visits as per standard practice at the site and agree to complete PRO questionnaires and other patient completed questions.\n\n9.2.2. Exclusion Criteria\n\nPatients meeting any of the following criteria will not be included in the study:\n\n1. Patients, that currently have active forms of other inflammatory skin diseases, other than AD or have evidence of skin conditions (eg, psoriasis, seborrheic dermatitis, Lupus) at the time of Day 1 that would interfere with evaluation of atopic dermatitis or response to treatment.\n2. Patients previously treated with abrocitinib or other oral\u002Fsystemic JAK inhibitors\n3. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family.\n4. Patient eligibility should be reviewed, documented, and confirmed by an appropriately qualified member of the investigator's study team before patients are enrolled in the study.",{"count":40,"type":21},"This is a prospective, multi-center observational study characterizing clinical and patient reported outcomes of patients receiving abrocitinib for moderate-to-severe atopic dermatitis (M2S AD) who had inadequate response (or intolerance) to ≤2 previous biologic therapies approved for M2S AD in the United States.\n\nThe aim of this study is to measure the effectiveness of abrocitinib in a real-world setting in patients with moderate-to-severe atopic dermatitis, with inadequate response or intolerance to ≤2 biologic therapies.",[170,194,60],"Atopic Dermatitis, Unspecified",[196],"Real world efficacy","2026-04-17",{"date":199,"type":32},"2026-04-22",{"date":201,"type":32},"2026-01-13",{"date":203,"type":21},"2027-02-15",{"name":205,"class":39},"Pfizer",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":87,"enrollmentInfo":213,"targetDuration":4,"studyType":22,"phases":214,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":217,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":222,"leadSponsor":224,"locationsCount":78},"100634496","phase-3-a-phase-iii-study-of-mg-k10-in-adolescents-with-moderate-to-severe-atopic-dermatitis-100634496","NCT07540442","A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis","Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MG-K10 (a Humanized Monoclonal Antibody Injection) in Adolescents With Moderate-to-Severe Atopic Dermatitis","Inclusion Criteria:\n\n1. Diagnosis of Atopic Dermatitis (AD) per American Academy of Dermatology (2014) criteria for ≥6 months;\n2. Eczema Area and Severity Index (EASI) ≥16;\n3. Investigator's Global Assessment (IGA) ≥3;\n4. Body Surface Area (BSA) involvement ≥10%;\n5. Peak Pruritus Numerical Rating Scale (NRS) weekly average ≥4;\n6. Inadequate response to topical treatments within 6 months or medically inadvisable to use topical treatments.\n\nExclusion Criteria:\n\n1. Inability to tolerate venipuncture, or a history of needle phobia or hematophobia;\n2. Inability to receive subcutaneous injections, such as patients currently receiving anticoagulant therapy, or those with known bleeding disorders or idiopathic thrombocytopenic purpura;\n3. Presence of ophthalmic diseases judged by the investigator to be unsuitable for inclusion;\n4. Concurrent serious diseases including, but not limited to, cardiovascular, metabolic, or neurological diseases, which, in the opinion of the investigator, render the subject unsuitable for immunosuppressive therapy;\n5. History of parasitic infection within 6 months prior to screening;\n6. Planned major surgery during the study period;\n7. Prior or concomitant treatments meeting any of the following:\n\n   * Use of biologics within 10 weeks prior to randomization or within 5 half-lives (whichever is longer)\n   * Use of targeted inhibitors (e.g., JAK inhibitors), systemic glucocorticoids, cyclosporine, or other immunosuppressants (e.g., methotrexate, MMF, azathioprine), phosphodiesterase-4 (PDE4) inhibitors, phototherapy (UV), or systemic Chinese herbal medicine for AD within 4 weeks prior to randomization\n   * Use of topical treatments for AD (e.g., topical glucocorticoids, topical calcineurin inhibitors, antibiotic combination creams, or topical Chinese herbal medicine) within 2 weeks prior to randomization\n   * Receipt of live or attenuated vaccines within 3 months prior to randomization or plans to receive such vaccines during the study\n   * Participation in other clinical trials within 3 months or 5 half-lives (whichever is longer) prior to randomization, or plans to participate in other clinical trials during the study period\n   * Systemic anti-infective therapy (oral or intravenous antibacterial, antiviral, or antifungal) within 4 weeks prior to randomization, or current acute or subacute infection indicated by symptoms, signs, or laboratory abnormalities\n8. History of alcohol or drug abuse within 6 months prior to screening; Known allergy or intolerance to any component of the investigational product.\n9. Other conditions that, in the opinion of the investigator, make the subject unsuitable for participation in the study.",{"count":143,"type":21},[24],"This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of MG-K10 monotherapy in adolescents with moderate-to-severe atopic dermatitis (AD)",[60],"NOT_YET_RECRUITING","2026-04-13",{"date":220,"type":32},"2026-04-20",{"date":197,"type":21},{"date":223,"type":21},"2027-11-09",{"name":225,"class":39},"Shanghai Mabgeek Biotech.Co.Ltd",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":17,"minAge":233,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":239,"conditions":240,"keywords":241,"overallStatus":217,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":4},"100621231","phase-4-comparative-study-of-crisaborole-vs-tacrolimus-in-atopic-dermatitis-100621231","NCT07367932","Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis","Crisaborole 2% Versus Tacrolimus 0.03% Ointments for the Treatment of Mild to Moderate Atopic Dermatitis: A Comparative Study","Inclusion Criteria:\n\n* Patients with diagnosis of AD, according to Hanifin and Rajka criteria.\n* Patients of both genders\n* Age 5-25 years\n* Baseline Investigator's Static Global Assessment (ISGA) score of mild (2) or moderate (3).\n\nExclusion Criteria:\n\n* Clinically infected eczema.\n* Baseline Investigator's Static Global Assessment (ISGA) score of severe (4).\n* Associated comorbidities that exacerbate pruritus.\n* Patients receiving topical treatment for AD and\u002For pruritus within the past 14 days and\u002For systemic treatment within the past month.\n* Pregnancy and lactation if in the childbearing period","5 Years","25 Years",{"count":236,"type":21},30,[238],"PHASE4","This study will compare the efficacy and safety of crisaborole ointment with tacrolimus ointment, in the treatment of patients with mild-to-moderate atopic dermatitis.",[60,57],[242,243,244],"Tacrolimus","Crisaborole","Atopic dermatitis",{"date":246,"type":32},"2026-01-26",{"date":248,"type":21},"2026-02",{"date":250,"type":21},"2026-07",{"name":252,"class":253},"Cairo University","OTHER",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":263,"conditions":264,"keywords":265,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":78},"100469304","a-study-to-learn-about-the-study-medicine-called-cibinqo-in-people-with-atopic-dermatitis-100469304","NCT05391061","A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis","Post Marketing Surveillance (PMS) Study for Cibinqo Tablet (Abrocitinib) in Patients With Moderate to Severe Atopic Dermatitis (AD) in Korea","This study is seeking participants who should meet the usual prescribing criteria for Cibinqo® Tablets as per the Local Product Document (LPD) and should be entered into the study at the physician's discretion.\n\nInclusion Criteria:\n\n1. Patients with moderate to severe AD who have been determined to start treatment with Cibinqo Tablet according to the approved indications of the medicinal product.\n\n   • Atopic Dermatitis Cibinqo Tablet is indicated for the treatment of patients 12 years of age and older with moderate-to-severe atopic dermatitis who have required systemic therapies.\n2. Evidence of a personally signed and dated informed consent document indicating that the patient or their parent(s)\u002Flegal guardian, if applicable, have been informed of all pertinent aspects of the study\n\nExclusion Criteria:\n\n1. Patients who have previously received Cibinqo Tablet\n2. Patients concurrently participating in other studies involving therapeutic interventions and\u002For investigational products\n3. Patients who have contraindications to Cibinqo Tablet as specified in the approved LPD • Contraindications to Cibinqo Tablet\n\n   * Patients with platelet count \\\u003C150 × 103\u002Fmm3, an absolute neutrophil count (ANC) \\\u003C1 × 103\u002Fmm3, an absolute lymphocyte count (ALC) \\\u003C0.5 × 103\u002Fmm3 or who have a haemoglobin value \\\u003C8 g\u002FdL\n   * Hypersensitivity to the active substance or to any of the excipients\n   * Active serious systemic infetions, including tuberculosis(TB)\n   * Severe hepatic impairment\n   * Pregnancy and breast-feeding\n   * Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption",{"count":262,"type":21},1100,"The purpose of this non-interventional study is to learn about the safety and effectivness of Cibinqo Tablet for the possible treatment of atopic dermatitis (AD).\n\nAD is a long-lasting itchy red rash, caused by a skin reaction.\n\nThis study is seeking participants who:\n\n1. Are patients with moderate to severe AD who have been waiting to start treatment with Cibinqo\n2. Have evidence of a personally signed and dated informed consent document indicating that the patient or their parent(s) or legal guardian, have been informed of all important details of the study Investigators will collect and record the information on each participant's experiences with Cibinqo. This study medicine is a tablet which is taken by mouth. Participants will be observed for about a year. During this time, we will study the experiences of people receiving the study medicine to help us decide if the study medicine is safe and effective.",[60],[266],"Atopic Dermatitis, Abrocitinib, Cibinqo","2025-12-08",{"date":269,"type":32},"2025-12-09",{"date":271,"type":32},"2023-01-07",{"date":273,"type":21},"2027-11-22",{"name":205,"class":39},{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":87,"enrollmentInfo":282,"targetDuration":4,"studyType":22,"phases":283,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":295},"100596182","phase-3-evaluation-of-611-in-chinese-adolescents-with-moderate-to-severe-atopic-dermatitis-100596182","NCT07042126","Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis","A Multi-Center, Randomized, Double-Blind, Placebo-Ccontrolled Phase Ⅲ Clinical Trail， to Evaluate the Efficacy and Safety of 611 (Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adolescents (12 Years Old≤Age \u003C 18 Years Old) With Moderate to Severe Atopic Dermatitis (AD)","Inclusion Criteria:\n\n* The subjects and their legal guardians are able to understand and comply with the research procedures, agree to participate in the research, and sign the Informed Consent Form (ICF).\n* When signing the informed consent form, the age should be ≥ 12 years old and \\\u003C 18 years old, gender is not restricted, and the body weight should be ≥ 30 kg at the screening and baseline.\n* During the screening process, patients were diagnosed with atopic dermatitis (AD) according to the Hanifin - Rajka criteria, and their AD medical history was evaluated by researchers to be ≥ 6 months (the diagnostic criteria are not restricted for the medical history).\n* At the screening and baseline, the Eczema Area and Severity Index (EASI) score is ≥ 16 points.\n* At the screening and baseline, the Investigator Global Assessment (IGA) score is ≥3 points.\n* At the time of screening and baseline, the affected body surface area (BSA) by atopic dermatitis (AD) is ≥10%.\n* At baseline, the weekly average score of the Numerical Rating Scale (NRS) for pruritus was ≥ 4 points.\n* Subjects should have relevant medical records, other medical visit records, or other evidence within the previous year for researchers to evaluate. The subjects have poor efficacy of topical drug treatment, or are medically unsuitable for topical drug treatment.\n* Be willing to use a stable dose of emollient (moisturizer) on the affected areas of atopic dermatitis (AD) twice a day for at least 7 days before randomization and continue to use it throughout the study period.\n* Subjects with potential fertility (e.g., females who have experienced menarche or males who have had nocturnal emissions) must agree to avoid sexual activity or use highly effective contraceptive methods throughout the entire study period and for at least 3 months after the last dose of the medication.Subjects should have no plans for reproduction, sperm donation, or egg donation during the entire study period and for at least 3 months after the last dose of the medication.\n\nBe able to understand and complete (either independently or with the assistance of a guardian) the research - related questionnaire filling.\n\nExclusion Criteria:\n\n* Merge other skin comorbidities that may interfere with the research evaluation.\n* Combined with active parasitic infections (such as helminths) or suspected parasitic infections (subjects who have excluded active infections through clinical and\u002For laboratory examinations before randomization can be enrolled).\n* Any history of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).\n* Randomly select patients with any malignant tumor diagnosed within the past 5 years or currently having the disease (excluding basal cell carcinoma that has been cured for ≥ 1 year, local cutaneous squamous cell carcinoma, or carcinoma in situ of the cervix).\n* The subject had a severe infection requiring intravenous antibiotics and\u002For hospitalization within 4 weeks before randomization, or had an active infection requiring oral antibiotics within 2 weeks before randomization, and the investigator evaluated that there might be uncontrollable risks for the subject to participate in this study.\n* A history of known or suspected immunosuppression, including a history of invasive opportunistic infections (such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis); or those who, although the infection has resolved, are considered by the investigator to be likely to have frequent recurrences.\n* Those with evidence of active tuberculosis, or those who have had active tuberculosis in the past but cannot provide sufficient evidence of treatment, or those who are judged to potentially have active tuberculosis infection based on examinations such as chest X - ray or CT, medical history, contact history, symptoms, and physical signs.\n* The researchers believe that there are any diseases that are severe or unstable and may affect the safety of the subjects during the study and\u002For prevent the subjects from completing the study, including but not limited to cardiovascular, gastrointestinal, liver, kidney, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, and mental diseases.\n* Currently receiving or having received the following treatments:\n\n  1. Within the first 2 weeks randomly selected, patients have received topical drug treatment for atopic dermatitis (AD), such as TCS, TCI, PDE inhibitors, Janus kinase (JAK) inhibitors, etc.\n  2. Within the first 4 weeks before randomization, the patients received systemic treatment with traditional Chinese medicine (TCM) of unknown nature or with therapeutic effects on AD. Or within the first 1 week before randomization, they received topical treatment with Chinese herbal medicine of unknown nature or with therapeutic effects on AD.\n  3. Received systemic glucocorticoids or other immunosuppressants\u002Fimmunomodulators (including but not limited to cyclosporine, mycophenolate mofetil, interferon γ \\[IFN-γ\\], JAK inhibitors, compound glycyrrhizin, azathioprine, mycophenolate mofetil, and methotrexate) randomly within the first 4 weeks or 5 half - lives (whichever is longer).\n  4. Received phototherapy (including but not limited to narrow - band ultraviolet B \\[NBUVB\\], ultraviolet B \\[UVB\\], ultraviolet A1 \\[UVA1\\], psoralen plus ultraviolet A \\[PUVA\\]), tanning beds, or any other light - emitting devices with therapeutic effects on atopic dermatitis (AD) within the first 4 weeks randomly.\n  5. Randomly selected patients who had received allergen-specific immunotherapy (SIT) within the previous 6 months.\n  6. Received any monoclonal antibody therapy (such as dupilumab, etc.) within the first 4 months randomly or within 5 half-lives (whichever is longer) before randomization; Received any cell - depleting agents, including but not limited to rituximab, within 6 months before randomization.\n  7. As judged by the researchers, patients had no response or poor efficacy to previous treatment with anti-IL-4 and\u002For IL-13 drugs (such as dupilumab, etc.).\n  8. Previously, 611 was used.\n  9. Treatment of atopic dermatitis (AD) with prescription emollients or emollients containing additives is initiated during the screening period.\n* Received live vaccines or live attenuated vaccines within the first 4 weeks before randomization.\n* If any of the examination indicators before screening or randomization meet the following criteria and are judged by the researcher as unsuitable for inclusion in the study:TBIL≥1.5 ULN ;ALT\u002FAST ≥2 ULN；Cr\\>1.5 ULN; blood WBC is lower than LLN, which is judged by the researcher to be clinically significant and makes the subject ineligible for the study.\n* At the screening, the test results are positive for hepatitis B, positive for hepatitis C virus antibody (HCVAb), positive for human immunodeficiency virus antibody (HIVAb), and positive for serum Treponema pallidum antibody (TPAb).\n* Used any investigational drugs within the first 8 weeks after randomization or 5 half-lives (whichever is longer);\n* Had a history of alcohol or drug abuse within 6 months before randomization;\n* Known to be allergic or intolerant to any components of the investigational drug;\n* Planned or were expected to undergo major surgical operations during the study period;\n* Pregnant women, women planning to become pregnant during the study period, or breastfeeding women;\n* According to the investigator's judgment, the subjects were not suitable to participate in the study due to other diseases or reasons.",{"count":143,"type":21},[24],"The primary objective of the study was to evaluate the efficacy of 611 in Chinese Adolescents with moderate to severe atopic dermatitis.",[60],"2025-11-16",{"date":288,"type":32},"2025-11-18",{"date":290,"type":32},"2025-08-05",{"date":292,"type":21},"2027-09-30",{"name":294,"class":39},"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.",3,{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":304,"targetDuration":306,"studyType":89,"phases":4,"briefSummary":307,"conditions":308,"keywords":311,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":325},"100543224","abrocitinib-taiwan-treatment-pattern-and-real-world-study-in-atopic-dermatitis-attract-registry-100543224","NCT06353087","Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)","The Real-world Treatment Patterns and Clinical Outcomes in Moderate-to-severe Atopic Dermatitis (AD) Patients Receiving Abrocitinib","ATTRACT","Inclusion Criteria:\n\nPatients must meet all of the following inclusion criteria to be eligible for inclusion in the study:\n\n1. Patients aged ≥12 years\n2. Patients with confirmed diagnosis of moderate-to-severe AD as assessed by the physician\n3. Patients for whom the physician's decision has been made to newly prescribe abrocitinib in usual clinical practice conditions\n4. Evidence of a personally signed and dated informed consent\u002Fassent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will not be included in the study:\n\n1. Any prior use of abrocitinib\n2. Simultaneous participation in a study that includes administration of any investigational drug or procedure",{"count":305,"type":21},200,"12 Months","This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period, and to describe patient demographic and baseline characteristics.",[60,58,57,61,309,310],"Immune System Diseases","Janus Kinase Inhibitors",[170,312,313,314,315,316],"Abrocitinib","JAK inhibitors","Real world","Registry","Taiwan","2025-09-02",{"date":319,"type":32},"2025-09-03",{"date":321,"type":32},"2024-07-01",{"date":323,"type":21},"2026-05-15",{"name":205,"class":39},8,{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":48,"sex":17,"minAge":18,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":22,"phases":336,"briefSummary":338,"conditions":339,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":78},"100553642","the-efficacy-of-3-kanuka-oil-versus-1-hydrocortisone-cream-in-patients-with-atopic-dermatitis-100553642","NCT06488742","The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis","Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in the Treatment of Patients With Mild Atopic Dermatitis","Inclusion Criteria:\n\n* age greater than 12 years, diagnosis of atopic dermatitis for longer than 2 years, investigator's static global assessment score of either 2 or 3, and initial worst itch numerical rating scale (WI-NRS) for itch greater than 4.\n\nExclusion Criteria:\n\n* the use of topical or systemic corticosteroids within 28 days of entering the study, the use of any other non-emollient therapy within 28 days of entering the study,nursing, and pregnancy","75 Years",{"count":335,"type":21},60,[337],"NA","Atopic dermatitis is a common disease affecting millions worldwide. A common associated symptom in this population is pruritus. We seek to investigate the use of an natural, over-the-counter cosmeceutical to help this population",[60,340],"Pruritus","2024-06-28",{"date":343,"type":32},"2024-07-05",{"date":345,"type":32},"2023-11-01",{"date":347,"type":21},"2025-03-20",{"name":349,"class":39},"Nexgen Dermatologics, Inc.",{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":357,"targetDuration":233,"studyType":89,"phases":4,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":100},"100491097","spanish-academy-of-dermatology-and-venereology-registry-of-atopic-dermatitis-therapy-100491097","NCT05674695","Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy","BIOBADATOP","Inclusion Criteria:\n\n1. Paediatric and adult patients with atopic eczema who due to the severity of their disease and\u002For impact on quality of life are commencing on or switching to a specific systemic immuno-modulatory agent (e.g. CyA, AZA, MTX or new\u002Fbiologic treatments) for the first time in their life (might have received others, but not this specific one).\n2. Diagnosis of atopic eczema in keeping with the UK\u002FIrish diagnostic criteria.\n3. Willingness to comply with all study requirements.\n\nExclusion Criteria:\n\n1. Insufficient understanding of the study by the patient and\u002For parent\u002Fguardian.\n2. Patients who are currently participating in a randomised clinical trial.\n3. Intention to move to a different geographical area in a short-term (next 3 months).",{"count":358,"type":21},2500,"The Spanish Registry of Systemic therapy in atopic eczema, BIOBADATOP, assesses drug safety and treatment effectiveness as well as treatment impact on quality of life in children and adults with atopic eczema receiving systemic immuno-modulatory therapies in Spanish daily practice.\n\nThe main objectives are:\n\n1. To assess short and long-term safety of systemic therapies (including phototherapy) for atopic eczema (pharmacovigilance).\n2. To assess short and long-term effectiveness of systemic therapies, providing a basis for shared decision making and guidelines.\n\nSecondary objectives are:\n\n1. To assess short and long-term safety of topical therapies for atopic eczema.\n2. To assess effectiveness of different methods of care, including patient training.\n3. To describe atopic dermatitis comorbidities.",[60],"2023-01-05",{"date":363,"type":32},"2023-01-06",{"date":365,"type":32},"2019-01-01",{"date":367,"type":21},"2029-01-01",{"name":369,"class":253},"Fundación Academia Española de Dermatología"]